325 related articles for article (PubMed ID: 11349057)
21. Plasmodium yoelii: cloning and characterization of the gene encoding for the mitochondrial heat shock protein 60.
Sanchez GI; Carucci DJ; Sacci J; Resau JH; Rogers WO; Kumar N; Hoffman SL
Exp Parasitol; 1999 Dec; 93(4):181-90. PubMed ID: 10600443
[TBL] [Abstract][Full Text] [Related]
22. Immunogenicity of novel nanoparticle-coated MSP-1 C-terminus malaria DNA vaccine using different routes of administration.
Cherif MS; Shuaibu MN; Kurosaki T; Helegbe GK; Kikuchi M; Yanagi T; Tsuboi T; Sasaki H; Hirayama K
Vaccine; 2011 Nov; 29(48):9038-50. PubMed ID: 21939717
[TBL] [Abstract][Full Text] [Related]
23. Protection against malaria by Plasmodium yoelii sporozoite surface protein 2 linear peptide induction of CD4+ T cell- and IFN-gamma-dependent elimination of infected hepatocytes.
Wang R; Charoenvit Y; Corradin G; De La Vega P; Franke ED; Hoffman SL
J Immunol; 1996 Nov; 157(9):4061-7. PubMed ID: 8892640
[TBL] [Abstract][Full Text] [Related]
24. Cellular and humoral immune effector mechanisms required for sterile protection against sporozoite challenge induced with the novel malaria vaccine candidate CelTOS.
Bergmann-Leitner ES; Legler PM; Savranskaya T; Ockenhouse CF; Angov E
Vaccine; 2011 Aug; 29(35):5940-9. PubMed ID: 21722682
[TBL] [Abstract][Full Text] [Related]
25. Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine.
Sedegah M; Jones TR; Kaur M; Hedstrom R; Hobart P; Tine JA; Hoffman SL
Proc Natl Acad Sci U S A; 1998 Jun; 95(13):7648-53. PubMed ID: 9636204
[TBL] [Abstract][Full Text] [Related]
26. Targeting antigen to MHC Class I and Class II antigen presentation pathways for malaria DNA vaccines.
Dobaño C; Rogers WO; Gowda K; Doolan DL
Immunol Lett; 2007 Aug; 111(2):92-102. PubMed ID: 17604849
[TBL] [Abstract][Full Text] [Related]
27. Novel antigen identification method for discovery of protective malaria antigens by rapid testing of DNA vaccines encoding exons from the parasite genome.
Haddad D; Bilcikova E; Witney AA; Carlton JM; White CE; Blair PL; Chattopadhyay R; Russell J; Abot E; Charoenvit Y; Aguiar JC; Carucci DJ; Weiss WR
Infect Immun; 2004 Mar; 72(3):1594-602. PubMed ID: 14977966
[TBL] [Abstract][Full Text] [Related]
28. CD4(+) T-cell- and gamma interferon-dependent protection against murine malaria by immunization with linear synthetic peptides from a Plasmodium yoelii 17-kilodalton hepatocyte erythrocyte protein.
Charoenvit Y; Majam VF; Corradin G; Sacci JB; Wang R; Doolan DL; Jones TR; Abot E; Patarroyo ME; Guzman F; Hoffman SL
Infect Immun; 1999 Nov; 67(11):5604-14. PubMed ID: 10531206
[TBL] [Abstract][Full Text] [Related]
29. Production, characterisation and immunogenicity of a plant-made Plasmodium antigen--the 19 kDa C-terminal fragment of Plasmodium yoelii merozoite surface protein 1.
Ma C; Wang L; Webster DE; Campbell AE; Coppel RL
Appl Microbiol Biotechnol; 2012 Apr; 94(1):151-61. PubMed ID: 22170105
[TBL] [Abstract][Full Text] [Related]
30. Escheriosome entrapped soluble blood stage antigens impart protective immunity against a multi-drug resistant isolate of Plasmodium yoelii nigeriensis in BALB/c mice.
Sharma SK; Farah D; Misra-Bhattacharya S; Bajpai P; Agarwal A; Mohammad O
Vaccine; 2006 Feb; 24(7):948-56. PubMed ID: 16168527
[TBL] [Abstract][Full Text] [Related]
31. Artesunate versus chloroquine infection-treatment-vaccination defines stage-specific immune responses associated with prolonged sterile protection against both pre-erythrocytic and erythrocytic Plasmodium yoelii infection.
Peng X; Keitany GJ; Vignali M; Chen L; Gibson C; Choi K; Huang F; Wang R
J Immunol; 2014 Aug; 193(3):1268-77. PubMed ID: 24958899
[TBL] [Abstract][Full Text] [Related]
32. Suppression of lethal Plasmodium yoelii malaria following protective immunization requires antibody-, IL-4-, and IFN-gamma-dependent responses induced by vaccination and/or challenge infection.
Petritus PM; Burns JM
J Immunol; 2008 Jan; 180(1):444-53. PubMed ID: 18097046
[TBL] [Abstract][Full Text] [Related]
33. Plasmodium yoelii blood-stage antigens newly identified by immunoaffinity using purified IgG antibodies from malaria-resistant mice.
Kamali AN; Marín-García P; Azcárate IG; Diez A; Puyet A; Bautista JM
Immunobiology; 2012 Aug; 217(8):823-30. PubMed ID: 22658767
[TBL] [Abstract][Full Text] [Related]
34. Linear and multiple antigen peptides containing defined T and B epitopes of the Plasmodium yoelii circumsporozoite protein: antibody-mediated protection and boosting by sporozoite infection.
Marussig M; Rénia L; Motard A; Miltgen F; Pétour P; Chauhan V; Corradin G; Mazier D
Int Immunol; 1997 Dec; 9(12):1817-24. PubMed ID: 9466309
[TBL] [Abstract][Full Text] [Related]
35. A bicistronic DNA vaccine containing apical membrane antigen 1 and merozoite surface protein 4/5 can prime humoral and cellular immune responses and partially protect mice against virulent Plasmodium chabaudi adami DS malaria.
Rainczuk A; Scorza T; Spithill TW; Smooker PM
Infect Immun; 2004 Oct; 72(10):5565-73. PubMed ID: 15385453
[TBL] [Abstract][Full Text] [Related]
36. Immunological responses of neonates and infants to DNA vaccines.
Sedegah M; Hoffman SL
Methods Mol Med; 2006; 127():239-51. PubMed ID: 16988458
[TBL] [Abstract][Full Text] [Related]
37. Human antibodies against Plasmodium falciparum liver-stage antigen 3 cross-react with Plasmodium yoelii preerythrocytic-stage epitopes and inhibit sporozoite invasion in vitro and in vivo.
Brahimi K; Badell E; Sauzet JP; BenMohamed L; Daubersies P; Guérin-Marchand C; Snounou G; Druilhe P
Infect Immun; 2001 Jun; 69(6):3845-52. PubMed ID: 11349050
[TBL] [Abstract][Full Text] [Related]
38. Immunogenicity, protective efficacy and safety of a recombinant DNA vaccine encoding truncated Plasmodium yoelii sporozoite asparagine-rich protein 1 (PySAP1).
Zhao J; Deng S; Liang J; Cao Y; Liu J; Du F; Shang H; Cui L; Luo E
Hum Vaccin Immunother; 2013 May; 9(5):1104-11. PubMed ID: 23357857
[TBL] [Abstract][Full Text] [Related]
39. Induction of long-lasting immunity to Plasmodium yoelii malaria with whole blood-stage antigens and copolymer adjuvants.
Hunter RL; Kidd MR; Olsen MR; Patterson PS; Lal AA
J Immunol; 1995 Feb; 154(4):1762-9. PubMed ID: 7836760
[TBL] [Abstract][Full Text] [Related]
40. Long-lasting protective immune response to the 19-kilodalton carboxy-terminal fragment of Plasmodium yoelii merozoite surface protein 1 in mice.
Jeamwattanalert P; Mahakunkijcharoen Y; Kittigul L; Mahannop P; Pichyangkul S; Hirunpetcharat C
Clin Vaccine Immunol; 2007 Apr; 14(4):342-7. PubMed ID: 17314232
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
